North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 15 of 15
Details
UPD
sitematrix Changed from 0 to
27/07/2022 08:41:30
(LoweryM )
UPD
FurtherInformation Changed from
150mg subcutaneous injection
Approved for the treatment of highly active relapsing-remitting mutiple sclerosis that has failed to respond to other treatment in adults in line with NICE and NHS England Comm
27/07/2022 08:41:30
(LoweryM )
UPD
Daclizumab (Zinbryta
®
) formatting
27/07/2022 08:41:30
(LoweryM )
UPD
Published from Draft Mode
27/10/2017 14:57:30
(DavidS )
UPD
Daclizumab (Zinbryta
®
) updated
27/10/2017 14:56:03
(DavidS )
UPD
Daclizumab (Zinbryta
®
) updated
26/10/2017 10:49:46
(DavidS )
LDL
Link Added : EMA Supporting Document restricting access to daclizumab : http://www.ema.europa.eu/docs/en GB/document library/Press release/2017/07/WC500230922.pdf
26/10/2017 10:49:18
(DavidS )
UPD
Daclizumab (Zinbryta
®
) updated with EMA guidance and link
26/10/2017 10:46:48
(DavidS )
UPD
Daclizumab (Zinbryta
®
) approved
11/08/2017 14:21:05
(LoweryM )
UPD
Daclizumab (Zenapax
®
) approved
11/08/2017 14:13:46
(LoweryM )
UPD
Daclizumab (Zenapax
®
) updated
09/08/2017 17:31:47
(DavidS )
LDL
Link Added : NICE TA441 Daclizumab for treating relapsing–remitting multiple sclerosis : https://www.nice.org.uk/guidance/ta441
09/08/2017 17:31:32
(DavidS )
UPD
Daclizumab (Zenapax
®
) updated
09/08/2017 17:31:08
(DavidS )
UPD
Daclizumab (Zenapax
®
) NICE TA441 APC July 2017
09/08/2017 17:30:39
(DavidS )
UPD
Status Changed to | Hidden | Published
22/03/2017 15:10:45
(DavidS )
